Company Aditxt, Inc.

Equities

ADTX

US0070256047

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.39 ^USD	-5.53%		+1.70%	-63.95%

Apr. 16	Aditxt, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 02	Appili Therapeutics To be Acquired by Aditxt, Inc.	MT

Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.

Number of employees: 47

USD in Million	2022	Weight	2023	Weight	Delta
Immune Reprogramming Technologies 100.0 %	1	100.0 %	1	100.0 %	-30.90%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	1	100.0 %	1	100.0 %	-30.90%

Managers	Title	Age	Since
Shahrokh Shabahang FOU	Founder	61	17-09-27
Amro Albanna CEO	Chief Executive Officer	54	17-09-27
Thomas Farley DFI	Director of Finance/CFO	51	20-09-30
Rowena Albanna COO	Chief Operating Officer	58	20-07-09
Jennifer Lee HRO	Human Resources Officer	-	20-12-31
Dolly B. Tyan PRN	Corporate Officer/Principal	-	21-01-28
Corinne Pankovcin PRN	Corporate Officer/Principal	57	20-07-01

Members of the board	Title	Age	Since
Jeffrey Runge BRD	Director/Board Member	67	20-07-09
Amro Albanna CEO	Chief Executive Officer	54	17-09-27
Shahrokh Shabahang FOU	Founder	61	17-09-27
Brian Brady BRD	Director/Board Member	46	18-11-30
Charles Nelson BRD	Director/Board Member	71	Nov. 02

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,665,265	1,623,762 ( 97.51 %)	51 ( 0.003063 %)	97.51 %

Name	Equities	%	Valuation
Sabby Management LLC 1.124 %	22,048	1.124 %	74 963 $
UBS Securities LLC 0.0984 %	1,931	0.0984 %	6 565 $
Tower Research Capital LLC 0.0498 %	977	0.0498 %	3 322 $
Qube Research & Technologies Ltd. (France) 0.0357 %	700	0.0357 %	2 380 $
Shahrokh Shabahang 0.0284 %	557	0.0284 %	1 894 $
Glassman Wealth Services LLC 0.0255 %	500	0.0255 %	1 700 $
Amro Albanna 0.0193 %	378	0.0193 %	1 285 $
IFP Advisors, Inc. 0.0154 %	303	0.0154 %	1 030 $
Natixis SA 0.0127 %	250	0.0127 %	850 $
Matthew Shatzkes 0.0101 %	199	0.0101 %	677 $

Name	Equities	%	Valuation
Amro Albanna 100.00 %	1	100.00 %	3 $

Aditxt, Inc.

737 North Fifth Street Suite 200

23219, Richmond

http://www.aditxt.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ADITXT, INC.	-63.95%	3.98M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs